Trump administration tried to pay Germans for coronavirus treatment

• President Donald Trump apparently attempted to poach German researchers dealing with a treatment for the coronavirus so he could secure special rights to a prospective vaccine for the United States only.
• Paper WELT am Sonntag reported that Trump’s administration had offered large sums of money to Germany-based biotech business CureVac to protect rights for the vaccine work, “however just for the USA.”
• The German government is battling back, offering financial rewards to the business to remain in Germany.
• Karl Lauterbach, a senior German political leader and teacher of public health, said in reaction to the report: “The special sale of a possible vaccine to the U.S.A. must be avoided by all ways. Industrialism has limits.”
• CureVac stated it has been in contact with numerous companies and worldwide authorities, however denied “reports of an acquisition” in a statement Sunday to Business Expert.
• Check out Company Insider’s homepage for more stories

President Donald Trump reportedly attempted to hire German researchers working on a treatment for the coronavirus and used big sums of money to secure special rights to their work for the US, according to a report which was confirmed by the German federal government.

Prominent German paper WELT am Sonntag reported that Trump had used large sums of money to tempt the Germany-based business CureVac to the United States and to protect exclusive rights to a vaccine.

The firm works with the federally-owned Paul Ehrlich Institute for Vaccines and Biomedical Medicines on a remedy for the coronavirus.

The newspaper stated the German government is fighting back by providing monetary rewards to the company if it remains in Germany.

A German health ministry representative informed WELT am Sonntag that the government was involved in “intensive” conversations with CureVac about keeping the business headquartered in the UK.

” The German government is extremely interested in guaranteeing that vaccines and active substances against the brand-new coronavirus are also developed in Germany and Europe,” the paper quoted a Health Ministry authorities as saying.

He said a low-dose vaccine that the business hoped to develop could make it appropriate for mass production within CureVac’s existing facilities.

In a declaration last week, CureVac said that outgoing chief executive Daniel Menichella had been welcomed to the White Home for a conference with President Trump to go over techniques and chances for the production of a coronavirus vaccine.

Karl Lauterbach, a senior German political leader and teacher of health economics and public health, said in action to the story: “The unique sale of a possible vaccine to the U.S.A. must be prevented by all ways.

• Read more:
• There are at least 35 possible coronavirus vaccines in the works, intending to halt the pandemic. Here are the leading efforts to watch and what to expect in 2020 and beyond.
• The US is running to establish a coronavirus vaccine or treatment. Here’s how 10 leading drugmakers are racing to tackle the pandemic.
• A dripped presentation exposes the document US healthcare facilities are using to get ready for a major coronavirus break out. It approximates 96 million United States coronavirus cases and 480,000 deaths.
• How Italy spiraled from a completely healthy country to near collapse in 24 days as the coronavirus took hold

%%.

source https://jobsearchtips.net/trump-administration-tried-to-pay-germans-for-coronavirus-treatment/